LEXINGTON, MA, USA I July 16, 2025 I Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New ...

We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...

SEONGNAM, South Korea I July 17, 2025 I SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to ...

First-in-human study of MOMA-341 focuses on advanced or metastatic solid tumors with high microsatellite instability - ...

LONDON, UK and NEW YORK, NY, USA I July 16, 2025 I OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing ...

I Otsuka Pharmaceutical Co., Ltd. (Otsuka) has entered into an asset purchase agreement with Cantargia AB (Cantargia) for the acquisition of ...

NEW YORK, NY, USA I July 15, 2025 I SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical ...

The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse ...

PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, ...

I Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...